Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg/m²

NCT07462663 is registered in ClinicalTrials.gov with Hospital Universitari de Bellvitge as lead sponsor.

NCT NCT07462663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07462663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg/m²
Lead sponsor
Hospital Universitari de Bellvitge
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2035
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atypical endometrial hyperplasia, atypical endometrial hyperplasia and endometrial carcinoma stage i, bmi>40, endometrial cancer, endometrial cancer stage i, endometrial intraepithelial neoplasia, obesity, obesity & overweight, obesity grade iii